Exelixis to Release Second Quarter 2019 Financial Results on Wednesday, July 31, 2019
– Conference Call and Webcast to Follow at 5:00 p.m. EDT / 2:00 p.m. PDT – ALAMEDA, Calif.–(BUSINESS WIRE)–Exelixis, Inc.…
Pharmaceuticals, Biotechnology and Life Sciences
– Conference Call and Webcast to Follow at 5:00 p.m. EDT / 2:00 p.m. PDT – ALAMEDA, Calif.–(BUSINESS WIRE)–Exelixis, Inc.…
Novartis said Tuesday that the USFDA marked its investigational sickle cell drug crizanlizumab for Priority Review, which could be the first monoclonal antibody targeting the P-selectin mediated multi-cellular adhesion in sickle cell disease.
Continued growth in 2019 marked by new HD-X product launch, acquisition of the leading neurofilament light (Nf-L) antibody supplier, new…
City of Hope’s Arthur D. Riggs, Ph.D., a world-renowned expert in molecular biology and diabetes, and his wife, Jane, established…
ALACHUA, Fla.–(BUSINESS WIRE)–CTD Holdings, Inc. (OTCQB: CTDH), a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of disease…
Taris Bio has dosed the first patient in a test of its investigational product TAR-200 combined with Bristol-Myers Squibb’s Opdivo.
Biomarck Pharmaceuticals has improved the Overall Response Rate (ORR) in the BIO-11006/SOC group compared to standard of care alone at 3 months in the Phase 2 study in NSCLC, which compares standard of care alone, to SOC plus BIO-11006 in 60 patients with stage 4.
Trovagene has started erolling patients for its second phase study of onvansertib plus FOLFIRI and Avastin (bevacizumab) for second-line treatment of patients with metastatic colorectal cancer (mCRC) with a KRAS mutation.
Catalyst adopts unified platform approach to immediately offer impactful and competitive services for biopharmaceutical companies New full service offerings adopt…
Glenmark Pharmaceuticals got the final approval by the US FDA for its Ranolazine Extended-Release Tablets, generic version of Gilead’s Ranexa.